Latest news with #BairdMedical
Yahoo
19-05-2025
- Business
- Yahoo
Baird Medical Engages Global Clinical Leaders at AAES 2025
NEW YORK, May 19, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES), taking place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin. The AAES Annual Meeting, a premier academic and clinical forum, convenes leading endocrine surgeons, researchers, and innovators globally to explore advancements in endocrine surgery. For Baird Medical, this event is a key platform to showcase its latest MWA technological achievements and to foster direct engagement with healthcare professionals, thereby gaining deeper insights into the evolving needs of the medical community. At this year's meeting, Baird Medical presented its pioneering MWA system for thyroid nodule treatment, emphasizing its benefits as a minimally invasive alternative to conventional surgery. The technology garnered considerable interest from attending surgeons, who recognized its potential to enhance patient outcomes by minimizing procedural risks, preserving thyroid function, and expediting recovery. Through substantive dialogues with clinical experts, Baird Medical acquired critical feedback on practical aspects including patient selection, ultrasound guidance optimization, and diverse application scenarios. The insights and perspectives gathered at AAES 2025 are pivotal for shaping Baird Medical's future clinical collaboration initiatives. By maintaining a close alignment with the requirements of surgeons and their patients, the Company remains committed to advancing its mission of delivering safer, more effective treatment solutions for thyroid and other endocrine diseases. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact:Eric Huang, PR LiaisonBaird Medical Investment Holdings +1 (888) 508-6228Email: ir@ View original content to download multimedia: SOURCE BDMD Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Baird Medical Engages Global Clinical Leaders at AAES 2025
NEW YORK, May 19, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is pleased to announce its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES), taking place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin. The AAES Annual Meeting, a premier academic and clinical forum, convenes leading endocrine surgeons, researchers, and innovators globally to explore advancements in endocrine surgery. For Baird Medical, this event is a key platform to showcase its latest MWA technological achievements and to foster direct engagement with healthcare professionals, thereby gaining deeper insights into the evolving needs of the medical community. At this year's meeting, Baird Medical presented its pioneering MWA system for thyroid nodule treatment, emphasizing its benefits as a minimally invasive alternative to conventional surgery. The technology garnered considerable interest from attending surgeons, who recognized its potential to enhance patient outcomes by minimizing procedural risks, preserving thyroid function, and expediting recovery. Through substantive dialogues with clinical experts, Baird Medical acquired critical feedback on practical aspects including patient selection, ultrasound guidance optimization, and diverse application scenarios. The insights and perspectives gathered at AAES 2025 are pivotal for shaping Baird Medical's future clinical collaboration initiatives. By maintaining a close alignment with the requirements of surgeons and their patients, the Company remains committed to advancing its mission of delivering safer, more effective treatment solutions for thyroid and other endocrine diseases. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact:Eric Huang, PR LiaisonBaird Medical Investment Holdings +1 (888) 508-6228Email: ir@ View original content to download multimedia: SOURCE BDMD
Associated Press
02-04-2025
- Business
- Associated Press
Baird Medical Showcases Advanced MWA Technology with UCSF Expert in Guangzhou and Shenzhen
NEW YORK, April 2, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ('Baird Medical' or the 'Company') proudly hosted Dr. Quan-Yang Duh, a world-renowned endocrine surgeon and Chief of Endocrine Surgery at the University of California, San Francisco (UCSF), for an in-depth clinical observation visit in Guangzhou and Shenzhen, China. During his visit, Dr. Duh closely examined the real-world application of Baird Medical's advanced microwave ablation (MWA) technology. In Guangzhou, Dr. Duh visited several prestigious hospitals, where he observed a range of thyroid ablation cases. One particularly notable case involved a patient with bilateral thyroid nodules, including a 4 cm lesion, successfully treated using Baird Medical's MWA system. The procedure, performed by Dr. Feng Han, a leading MWA specialist at Sun Yat-sen University Cancer Center, was executed with remarkable precision and efficiency. The patient remained fully awake and comfortable throughout underscoring the minimally invasive nature of the procedure. 'The case was highly educational,' said Dr. Duh. 'Dr. Han demonstrated exceptional expertise, and the speed and accuracy of the procedure highlight both the skill of the medical team and the medical team and the sophistication of the technology.' Following the procedure, Dr. Duh engaged in in-depth academic discussions with Dr. Feng Han and Dr. Jian Hua Zhou, Chief of Interventional Radiology at Sun Yat-sen University Cancer Center, further fostering international collaboration in thyroid ablation advancements. Dr. Duh continued his visit in Shenzhen, where he observed additional MWA procedures at one of the city's leading thyroid hospitals. He also participated in academic discussions with top specialists in the field and delivered a presentation titled 'Advances in Surgical Management of Thyroid and Parathyroid Diseases.' His talk provided valuable insights into the latest developments in endocrine surgery and facilitated an in-depth exchange on the growing role of microwave ablation in thyroid treatment, particularly its integration with surgical approaches. 'We are honored to facilitate these global academic exchanges and showcase the clinical impact of our MWA technology,' said Haimei Wu, Chairwoman of Baird Medical. 'As we continue to expand, we remain committed to driving innovation and working alongside top-tier medical professionals to enhance the accessibility and precision of minimally invasive thyroid treatments.' As Baird Medical continues its global expansion, the Company remains dedicated to pioneering advancements in microwave ablation technology and forging strategic partnerships that redefine the future of thyroid care. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as 'may', 'could', 'should', 'expect', 'intend', 'might', 'will', 'estimate', 'anticipate', 'believe', 'budget', 'forecast', 'intend', 'plan', 'potential', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled 'Risk Factors' therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Baird Medical Investment Holdings Ltd.
Associated Press
17-03-2025
- Business
- Associated Press
Baird Medical's AI Tumor Ablation Surgical Robot Wins 'Most Valuable Investment Award,' Pioneering AI and Robotics Integration in Healthcare
NEW YORK, March 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ('Baird Medical' or the 'Company') has been honored with the 'Most Valuable Investment Award' at the 10th China Medical Industry Innovation Competition with its revolutionary in-development product, the 'AI Tumor Ablation Surgical Robot.' This prestigious recognition marks a significant milestone in the advancement of AI and robotics integration that Baird Medical is developing in the medical field. AI & Robotics: Redefining the Paradigm of Precision Medicine Baird Medical's AI Tumor Ablation Surgical Robot will be an intelligent surgical system that seamlessly integrates multimodal AI algorithms with high-precision robotic arm control. Its key innovations will include: Autonomous Decision-Making & Dynamic Optimization – Using an AI-powered real-time learning framework, the system simultaneously analyzes intraoperative imaging, physiological data, and thermal field simulations to dynamically adjust ablation parameters with millimeter-level precision. Multi-Technology Synergy Platform – Integrating microwave, radiofrequency, laser, and nano-knife ablation technologies, the AI algorithm optimizes surgical site selection, nodule characteristics, energy output, and ablation method, overcoming the limitations of traditional single-technique approaches. End-to-End Intelligent Automation: Leveraging AI-driven precision, the system seamlessly integrates preoperative 3D lesion segmentation, millimeter-level path planning, and intraoperative micron-level fully automated surgery, followed by predictive postoperative outcome analysis. Surgeons serve as overseers, intervening only at critical junctures in a passive mode as needed. This transformative approach will effectively enhance surgical efficiency. As the 'brain' of the system, Baird Medical's proprietary AI-driven platform will offer three key technological advantages: Establishing an Extensive Medical Knowledge Base – Integrates over 100,000 tumor ablation image cases and 50,000 pathology reports, enabling cross-modal data correlation and in-depth analysis. Building a Self-Evolving Learning Architecture – Utilizes federated learning technology to enable secure data sharing across global partner hospitals, reducing model iteration cycles to just a few weeks. Implementing Quantum-Optimized Pretraining – In future collaboration with quantum computing centers, leverages quantum optimization algorithms to overcome the computational bottlenecks of traditional deep learning, significantly accelerating inference speed. World-Class R&D Team & Cutting-Edge Development: A Milestone in Medical Technology This project will actively implement Baird Medical's R&D strategy of 'Global Expertise + Local Innovation,' built on three core pillars. Building an Elite Interdisciplinary Team – Bringing together top-tier medical robotics experts from Nanyang Technological University, globally renowned oncologic surgeons, and former AI algorithm engineers from the Chinese Academy of Sciences. This core team has deep expertise in AI-driven medical applications and has collectively filed over 90 patents. Establishing a Comprehensive Validation Framework – Implementing rigorous multi-center clinical simulations across 20 top-tier hospitals in the U.S., Europe, and China to ensure the system's safety, reliability, and efficacy in complex surgical environments. Advancing an Ethics-Driven AI Design – Developing the world's first AI-powered surgical ethics decision module, incorporating real-time risk alerts and redundant operation validation to proactively mitigate surgical complications, with a targeted reduction to below 1%. Expanding Applications: From Tumor Treatment to a Minimally Invasive Revolution This cutting-edge system extends beyond the precise ablation of solid tumors such as thyroid nodules, breast nodules, liver cancer, and lung cancer—it also marks a breakthrough in chronic pain management. More notably, its modular design is expected to enable rapid adaptation for applications in neurosurgery (e.g., epilepsy lesion localization) and urology (e.g., prostate ablation). The launch of Baird Medical's AI-powered tumor ablation robotic system represents not only a paradigm shift in the integration of AI and robotics but also a redefinition of excellence in medical innovation. By harnessing deep learning as the foundation for next-generation medical AI, the system is transforming minimally invasive surgery from an experience-based practice to a data-driven discipline. As commercial deployment expands across 30+ countries, the future of intelligent healthcare is now within reach. The development of Baird Medical's AI-powered tumor ablation surgical robot will not only set a benchmark for the integration of AI and robotics but also redefine the standards for high-quality medical innovation. By harnessing deep learning as the foundation for next-generation medical AI, the system aims to transform minimally invasive surgery from an experience-based practice to a data-driven one. If successfully commercialized, the system is expected to initiate regulatory approvals and market expansion across more than 30 countries, bringing the future of intelligent healthcare within reach. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as 'may', 'could', 'should', 'expect', 'intend', 'might', 'will', 'estimate', 'anticipate', 'believe', 'budget', 'forecast', 'intend', 'plan', 'potential', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled 'Risk Factors' therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact:
Associated Press
03-03-2025
- Business
- Associated Press
Baird Medical Showcases Cutting-Edge MWA Innovations at NASOIE 2025
NEW YORK, March 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ('Baird Medical' or the 'Company'), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, made a lasting impact at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah. As a premier gathering for experts in interventional endocrinology, NASOIE serves as a platform for advancing minimally invasive treatments for thyroid and parathyroid disorders. The event convenes top-tier clinicians and researchers to explore the latest breakthroughs in treating thyroid nodules and cancer recurrences. Baird Medical's presence at NASOIE 2025 drew strong engagement, with numerous physicians visiting the booth to explore the latest advancements in MWA technology. Attendees participated in hands-on thyroid phantom demonstrations, experiencing firsthand the precision, safety, and efficiency of Baird's technology. The Company's experts engaged in in-depth discussions, addressing key clinical considerations and providing practical insights into MWA's role in thyroid care. Through these interactions, Baird Medical further solidified its leadership in next-generation thyroid ablation therapies, enhancing industry awareness, and reinforcing its commitment to innovation in minimally invasive treatment solutions. Baird Medical remains dedicated to advancing minimally invasive thyroid treatments by working closely with medical experts and industry leaders. The insights gained from NASOIE 2025 will help further refine the Company's MWA technology, ensuring it meets the evolving needs of thyroid care. Through continued research, education, and collaboration, Baird Medical is committed to improving treatment options for patients with thyroid nodules and related conditions worldwide. About Baird Medical Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' or the negative of these terms or other similar expressions. These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance. Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement. Contact: Baird Medical Investment Holdings Ltd.
